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AIMS  
Antiplatelet drugs are often discontinued early after ischaemic stroke, either because of poor 
compliance, complications or withdrawal of care. It is unclear whether this places patients at 
increased risk of recurrence. We explored the association between cardiovascular event rate 
and persistence with prescribed antiplatelet drugs. 
METHODS 
We used a matched case-control design using the Virtual International Stroke Trials Archive 
(VISTA). Cases were patients who had an acute coronary syndrome, recurrent stroke or 
transient ischaemic attack within 90 days post-stroke and were matched for age ±10 years 
and sex with up to four controls. Antiplatelet use was categorized as persistent (used for > 3 
days and continued up to day 90), early cessation (used antiplatelet < 3 days) or 
stopped/interrupted users (used for > 3 days but stopped prior to day 90). These categories 
were compared in cases and controls using a conditional logistic regression model that 
adjusted for potential confounders. 
RESULTS  
A total of 970 patients were included, of whom 194 were cases and 776 were matched 
controls. At 90 days, 10 cases (5.2%) and 58 controls (7.5%) stopped/interrupted their 
antiplatelet. The risk of cardiovascular event was not different in stopped/interrupted users 
(adjusted OR 0.70, 95% CI 0.33, 1.48; P=0.352) and early cessations (adjusted OR 1.04, 
95% CI 0.62, 1.74; P=0.876) when compared to persistent users. 
CONCLUSION  
We found no increased risk in patients who stopped and interrupted antiplatelets early after 
stroke but the study was limited by a small sample size and further research is needed. 
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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT 
Antiplatelet therapy is recommended for secondary prevention after ischaemic stroke.  
Interrupting or stopping antiplatelet therapy increases the risk of cardiovascular events. 
 
WHAT THIS STUDY ADDS 
The study did not demonstrate a significantly increased risk with stopping or interrupting 
antiplatelet use early afte stroke. This may reassure clinicians that, where interruption to 
therapy is needed for clinical reasons, there is not a significant increase in short term risk. 
 
 
Introduction 
There is a risk of recurrence following acute ischaemic stroke [1]. Antiplatelet therapy is 
given to reduce this risk and the risk of other vascular outcomes [2, 3]. National Institute for 
Health and Clinical Excellence (NICE) and Scottish Intercollegiate Guidelines Network 
(SIGN) guidelines recommend that antiplatelet therapy must be started early and continued 
indefinitely for long term secondary stroke prevention [3, 4]. In the UK guidelines favour 
aspirin therapy for 2-weeks followed by clopidogrel or the combination of low-dose aspirin 
and dipyridamole. 
 
Persistence with antiplatelet regimens is variable after stroke. Rates of aspirin 
discontinuation of less than 10% to almost 50% reported [5, 6]. At one year as many as 50% 
of patients who were prescribed aspirin or clopidogrel either discontinued, or failed to adhere 
to their regimen [7-9]. This may be for several reasons including patient non-compliance, 
bleeding complications, financial pressures, or physician directed withdrawal due to 
withdrawal of care, intercurrent illness or planned procedures [10]. Interrupting or stopping 
antiplatelet therapy may increase the risk of cardiovascular events in patients with a history 
of cardiovascular or cerebrovascular disease [11, 12]. One study found that among the 2197 
cases of ischaemic stroke, 5.2% cases occurred within 60 days after antithrombotic 
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withdrawal [10]. In this study, stroke events were clustered mostly in the first 7 days after 
stopping medication. Antithrombotic medication was stopped for various reasons including 
being stopped by physicians for procedures, patient compliance, bleeding complications and 
cost. In another study by García Rodríguez et al. [11], among 673 patients who had 
diagnosed with ischaemic stroke or TIA, 71.3% patients were taking aspirin on the day of 
event and 10% discontinued aspirin within 31-180 days before the event. On the other hand, 
a recent prospective observational study found that interruption of antiplatelet therapy due to 
surgical necessity was not associated with increased risk of cardiovascular events [13]. 
 
Data to demonstrate the impact of stopping antiplatelet therapy early after ischaemic stroke, 
where recurrence rate is highest are lacking. We aimed to explore the rate of antiplatelet 
cessation and interruption in a sample of patients with recent ischaemic stroke and assess 
the risk of cardiovascular events associated with cessation and interruption of antiplatelet 
drugs. 
 
Methods 
Study design 
We used a matched case-control study design to examine association between antiplatelet 
exposure and risk of a cardiovascular event. We used individual matching to identify up to 
four controls for each case, matched by age ±10 years and sex. We followed the STROBE 
guidance in  reporting this case-control study [14]. 
 
Data sources 
We used data from the Virtual International Stroke Trials Archive (VISTA) [15]. VISTA is a 
collaborative registry that collates and provides access to anonymised data from completed 
clinical trials. VISTA data are stored at the Robertson Centre for Biostatistics, University of 
Glasgow, Glasgow, UK. VISTA contains patients’ demographic data such as age, sex and 
ethnicity; smoking history and co-morbid conditions as well as details on the index stroke, 
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and functional outcome measures. Adverse events (AE) data, laboratory measurements and 
prescribed medications are available from certain trials. All trials lodged in VISTA already 
have local institutional review board approved procedures in accordance with the 
Declaration of Helsinki. Thus, our analysis does not require a new study approval. 
Nevertheless, access to data is subject to approval by the steering committee.  
 
Study cohort 
All acute ischaemic stroke patients in the VISTA who took antiplatelet therapy and had 
complete information on initiation day of antiplatelet therapy were identified. Patients with 
concurrent use of vitamin K antagonist such as warfarin were excluded as it may influence 
clinical [16] and safety [17] outcomes in acute ischaemic stroke patients. Patients who had a 
cardiovascular event within the first two days after ischaemic stroke were excluded as the 
event might not be associated to antiplatelet but due to the specific pattern of ischaemic 
changes after acute stroke [18]. 
 
Cases were defined as patients who had at least one cardiovascular event in the first 90 
days after acute ischaemic stroke. A cardiovascular event was defined as a acute coronary 
syndrome (ACS), recurrent ischaemic stroke or TIA. The event was identified from AE and 
SAE reports datasets using these key terms: (a) for ACS - unstable angina, acute coronary 
syndrome or myocardial infarction; (b) for recurrent ischaemic stroke -  stroke, cerebral 
infarction or cerebrovascular accident; and (c) TIA - transient ischaemic attack. Controls 
were identified from the same source to minimize the potential of bias [19]. Controls were 
defined as patients who had no cardiovascular event within 90 days after acute ischaemic 
stroke. The flowchart of patient’s selection are shown in Figure 1. The sample size was 
determined by the number of cases available in the study cohort. 
Antiplatelet drug exposure 
The information on antiplatelet drugs was obtained from the current medication dataset in 
VISTA. Data on start and stop dates of antiplatelet drugs were available on certain trials that 
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had monitored start and stop dates for all medications. Antiplatelet drugs were identified 
using the World Health Organization’s Anatomical Therapeutic Chemical (ATC) 
classifications i.e. antiplatelet with ATC code: B01AC. The antiplatelet exposure period for 
each patient began after the diagnosis of acute ischaemic stroke and ended at the index 
date. The index date was the date of the first cardiovascular event recorded after antiplatelet 
exposure in cases. In controls it was the same date as the matched case [20, 21]. Exposure 
to antiplatelet drugs prior to the index date was classified as persistent use, early cessation, 
interruption, or stopped (Figure 2). Persistent use was defined as taking antiplatelet therapy 
up to, or within 3 days of the index date. Patients who switching to another antiplatelet 
therapy were considered as continuing antiplatelet treatment. Early cessation was defined as 
patient who took antiplatelet therapy less than three days post-stroke or prior to the index 
date. Interruption was defined as  taking antiplatelet therapy up to, or within 3 days of the 
index date, but with two days or more interrupted use. Stopped was defined as stopping 
antiplatelet therapy at least 5 days before the index date.  
 
Bleeding events 
Bleeding events occurring during the study period were divided into two categories 
(intracerebral haemorrhage (ICH) and extracranial haemorrhage (ECH)). Intracerebral 
haemorrhage included all types of ICH except haemorrhagic transformation 1 and 2 of 
cerebral infarction, which were not counted.  ECH was defined as all other types of bleeding 
and was split into gastrointestinal (GI) and non-GI bleeding. These information were 
extracted from AE and SAE datasets in VISTA. 
 
Statistical analysis 
Descriptive statistics were recorded for cases and controls and according to the three types 
of antiplatelet exposures. The Chi-square test was used to compare baseline characteristics 
between cases and controls. Comparison between antiplatelet exposures group were 
conducted using the Kruskal-Wallis test or the chi-square test depending on the distribution 
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and nature of the data. Categorical variables were summarised using frequencies and 
proportions and continuous variables as mean [standard deviation (SD)] or median 
[interquartile range (IQR)].  
 
We used conditional logistic regression to calculate odds ratios (OR) and 95% confidence 
intervals (95% CI) for risk of cardiovascular event associated with exposures of antiplatelet 
before the index date. We first conducted univariable analyses. In multivariable analysis, we 
first included all significant variables (first model). We then consecutively dropped the least 
significant variable until all included variables were significant at P<0.05 (final model). A 
P<0.05 was considered significant. Point estimates and 95% CI are presented for all results. 
We used a complete-case approach to analysis so there was no imputation of missing data. 
All analyses were performed using IBM SPSS Statistics version 21.0 [22].  
 
A post-hoc power analysis to determine the power of the study and the sample size needed 
to detect a desired degree of statistical power was performed using PS (version 3.0 2009) to 
address the likelihood of type II error. 
 
Results 
Study population 
Complete data were available for analysis of antiplatelet exposure in 4050 patients. Of thses, 
a total of 194 patients who had at least one cardiovascular event (126 ischaemic stroke, 45 
ACS and 23 TIA) within 90 days following acute ischaemic stroke. These cases were 
matched to 776 controls. Baseline characteristics of patients with cardiovascular event and 
their matched controls are shown in Table 1. Compared with the control group, the cases 
were more likely to have a history of diabetes, heart failure and previous TIA. Among cases, 
there were 136 (70.1%) persistent users, 48 (24.7%) with early cessation and 10 (5.2%) 
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stopped/interrupted users. Among controls, there were 534 (68.8%) persistent users, 184 
(23.7%) early cessation and 58 (7.5%) stopped/interrupted users. 
 
Patients who interrupted/stopped their antiplatelet therapy had higher baseline NIHSS and 
were more likely to have previous ischaemic heart disease and stroke (Table 2) than 
persistent users. Aspirin was the most common antiplatelet prescribed followed by 
clopidogrel for both cases and controls (Table 3). More than two-third of persistent users, 
early cessation and interrupted/stopped users were exposed to aspirin and followed by 
clopidogrel (Table 4). The occurrence of bleeding events was highest in interrupted/stopped 
users (10.3%) followed by early cessation users (7.6%) (Table 5). 
 
Antiplatelet exposure and cardiovascular event 
There was no significant difference in cardiovascular event rate in early cessation and 
interrupted/stopped users compared to persistent users on univariable analysis (OR 1.07, 
95% CI 0.67, 1.71; P=0.784 and OR 0.67, 95% CI 0.34, 1.36; P=0.269 respectively) (Table 
6). Results were similar following adjustment (adjusted OR 1.04, 95% CI 0.62, 1.74; P=0.876  
and OR 0.70; 95% CI 0.33, 1.48; P=0.352 respectively) (Table 7). 
 
Discussion 
We performed a nested case-control study to explore the relationship between stopping or 
interrupting antiplatelet drugs and cardiovascular risk in patients with recent ischaemic 
stroke. We found no evidence for an increased risk of cardiovascular among patients who 
stopped or had interrupted use of antiplatelets.  
 
We found that the rates of early cessation of antiplatelet therapy were higher in our study 
compared to others [23, 24]. We defined early cessation as taking an antiplatelet for fewer 
than 3 days post-stroke or before a cardiovascular event. We used this definition because 
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most patients took aspirin and fewer than 3 days of aspirin use is unlikely to lead to full 
inhibition of platelets [25].  
 
Withdrawal of antiplatelets is associated with an increase in thromboxane A2 activity [26] 
which could increase the risk of ischaemic stroke [10, 11, 27]. These studies found that 
discontinuation of antiplatelet therapy within one to six months is associated with increased 
risk of ischaemic stroke or TIA. We did not see an increase and several factors could explain 
the difference between our findings and previous studies. First, our sample size was small 
compared to the studies by García Rodríguez, et al. [11] and Broderick, et al. [10] so there is 
a risk of type 2 error. Further, previous studies have assessed different time periods and 
clinical scenarios. The study cohort in García Rodríguez et al. was followed up for 
approximately 3.4 years. The STRATAGEM trial assessed the interruption of antiplatelets in 
patients undergoing surgery [28] and found no increased risk. This suggests the risk of 
stopping or interrupting antiplatelet drugs may be acceptable in the short term and we 
wished to assess whether this was the case after stroke. 
 
After stroke, there are several reasons why clinicians may be faced with decisions regarding 
continuing or stopping anti-platelets. These include bleeding complications and other 
adverse events such as worsening stroke symptoms or changes in haematological 
measures. At present, little data exist to inform these decisions in terms of risk of recurrence 
following cessation. Our study should reassure that, if clinically indicated, the short term risk 
of stopping anti-platelets does not appear to be significantly increased.  
 
In the present study, comorbidity was more common in cases and stroke severity was higher 
in patients who were interrupted or stopped users. We also found stroke severity, age, 
hypertension, diabetes and quality of life were related to the pattern of anti-platelet use. 
Patients with higher stroke severity, previous stroke and lower life quality were more likely to 
stop. Although we cannot be sure, this likely reflects the underlying reasons for stopping 
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treatment, such as change in clinical condition or withdrawal of care. Early cessation users 
had a higher rate of atrial fibrillation which may be explained by decisions to start 
anticoagulation therapy. On the other hand, interrupted/stopped users had a higher rate of 
bleeding suggesting this also influenced the reason to interrupt or stop antiplatelet therapy.  
 
Strengths and limitations 
Despite their known problems of bias and confounding, case-control designs are efficient in 
examining the association between outcomes and exposures. VISTA database sample 
provided data that were prospectively collected during clinical trials in patients with 
confirmed ischaemic stroke. We minimized selection bias by including all cases of 
cardiovascular event within the selected time period (day 3 up to 90 days) and matched 
controls, free of the outcome of interest and independent of the exposure of interest. 
Matching for age and sex increased the precision of our results compared with those of 
previous unmatched case-control studies. Information on exposures was recorded in the 
database, eliminating recall bias. 
 
An important limitation of this study is the lack of information on the underlying reasons for 
interruption/stopping of antiplatelets. This limits the generalizability of our findings to clinical 
practice. Generalizability is further limited by the fact that data come from a clinical trial 
registry and because most patients took aspirin and few received the combination of aspirin-
dipyridamole or clopidogrel as recommended in national and international guidelines. The 
main limitation is study power. Althought there is a large number of cases and controls, the 
number of patients with the different antiplatelet exposures was limited. Post hoc analysis 
revealed that this study, at alpha <0.05, with 194 cases and matched with four controls has 
insufficient power (0.239). Thus, to obtain 80% power, with the level of alpha 0.05, 801 
cases with 4 matched controls per case are needed. 
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Conclusion 
We found no significant association between interrupted or stopped use of antiplatelets and 
risk of cardiovascular events. This might reassure clinicians who need to stop antiplatelets 
for clinical reasons. However, our study had limited power and a clinically important risk 
cannot be excluded. Further research is needed. 
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Figures 
 
Figure 1. Flowchart of patients’ selection. 
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Figure 2. Determination of persistent user (a), early cessation user (b), interrupted user (c) 
and stopped user (d) of antiplatelet exposure. AP, antiplatelet; CV, cardiovascular event.  
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Table 1. Characteristics of patients with cardiovascular event and their matched controls 
Characteristics 
No. (%) 
p-value 
Overall 
n=970 
Cases 
n=194 
Controls 
n=776 
Age, years* 70.9(10.8) 70.9(11.3) 70.9(10.7) NA‡ 
Male sex 510(52.6) 102(52.6) 408(52.6) NA‡ 
Caucasian 808/934(86.5) 161/187(86.1) 647/747(86.6) 0.905 
Current Smoker 267/936(28.5) 60/187(32.1) 207/749(27.6) 0.240 
Baseline NIHSS† 12(8-17) 11.5(8-17) 12(8-17) 0.886 
Medical history     
Hypertension 692/947(73.1) 147/194(75.8) 545/753(72.4) 0.365 
Diabetes 228/970(23.5) 61/194(31.4) 167/776(21.5) 0.004 
Atrial fibrillation 159/947(16.8) 37/194(19.1) 122/753(16.2) 0.389 
Heart failure 65/859(7.6) 20/184(10.9) 45/675(6.7) 0.060 
Ischaemic heart 
disease 
243/915(26.6) 57/187(30.5) 186/728(25.5) 0.194 
Previous TIA 69/901(7.7) 19/176(10.8) 50/725(6.9) 0.084 
Previous stroke 177/886(20.0) 40/186(21.5) 137/700(19.6) 0.606 
rt-PA 318(32.8) 70(36.1) 248(32.0) 0.305 
Antiplatelet exposures     
Early cessation 232(23.9) 48(24.7) 184(23.7) 0.520 
Stopped/Interrupted 68(7.0) 10(5.2) 58(7.5)  
Persistent  670(69.1) 136(70.1) 534(68.8)  
*Values are reported as mean (SD); †median (IQR); ‡Variables that were matched and 
hence not applicable. CI, confidence interval; IQR, interquartile range; NIHSS, National 
Institute Health Stroke Scale; TIA, transient ischaemic attack; rt-PA, recombinant tissue 
plasminogen activator; SD, standard deviation.   
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Table 2. Distribution of risk factors for cardiovascular event by antiplatelet exposure 
Characteristics 
 No. (%)  
p-value Persistent 
user 
n=670 
Early 
cessation user 
n=232 
Interrupted/ 
Stopped user 
n=68 
Age, years* 70.2(10.9) 73.6(10.0) 69.1(11.3)  
Male sex 351(52.4) 122(52.6) 37(54.4) 0.951 
Ethnicity, 
Caucasian 
556/646 197/222 55/66 0.444 
(86.1) (88.7) (83.3)  
Current Smoker 
185/643 57/226 25/67 0.152 
(28.8) (25.2) (37.3)  
Baseline NIHSS† 11(8-16) 13(9-17) 17(12-20) <0.001 
Medical history     
Hypertension 
473/654 169/225 50/68 0.716 
(72.3) (75.1) (73.5)  
Diabetes 
164/670 51/232 13/68 0.502 
(24.5) (22.0) (19.1)  
Atrial fibrillation 
91/654 56/225 12/68 0.001 
(13.9) (24.9) (17.6)  
Heart failure 
38/601 21/196 6/62 0.105 
(6.3) (10.7) (9.7)  
Ischaemic heart 
disease 
146/628 74/220 23/67 0.004 
(23.2) (33.6) (34.3)  
Previous TIA 
48/623 16/212 5/66 0.997 
(7.7) (7.5) (7.6)  
Previous stroke 
111/617 48/207 18/62 0.049 
(18.0) (23.2) (29.0)  
rt-PA 224(33.4) 74(31.9) 20(29.4) 0.755 
*Values are reported as mean (SD); †median (IQR). CI, confidence interval; IQR, 
interquartile range; NIHSS, National Institute Health Stroke Scale; TIA, transient ischaemic 
attack; rt-PA, recombinant tissue plasminogen activator; SD, standard deviation. 
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Table 3. Characteristics of antiplatelet regimen prescribed  
Antiplatelet regimen 
No. (%) 
Unadjusted 
OR (95% CI) 
p-value Cases 
n=194 
Controls 
n=776 
Aspirin 139(71.6) 566(72.9) 1.00 - 
Clopidogrel 28(14.4) 105(13.5) 1.10 (0.69-1.74) 0.674 
Aspirin+Clopidogrel 10(5.2) 25(3.2) 1.63 (0.75-3.52) 0.215 
Aspirin+Dipyridamole 10(5.2) 50(6.4) 0.82 (0.40-1.68) 0.585 
Ticlopidine 4(2.1) 16(2.1) 1.01 (0.34-3.05) 0.980 
Aspirin+Ticlopidine 1(0.5) 1(0.1) 4.44 (0.28-71.29) 0.293 
Carbasalate 1(0.5) 5(0.6) 0.76 (0.09-6.73) 0.825 
Dipyridamole 1(0.5) 5(0.6) 0.79 (0.09-6.73) 0.825 
Ozagrel 0(0.0) 1(0.1) - - 
Triflusal 0(0.0) 2(0.3) - - 
CI, confidence interval; OR, odds ratio. 
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Table 4. Frequency of antiplatelet regimen according to types of antiplatelet exposure 
Antiplatelet regimen 
No. (%) 
p-value* Persistent 
user 
n=670 
Early  
cessation user 
n=232 
Interrupted/ 
Stopped user 
n=68 
Aspirin 492(73.4) 160(69.0) 53(77.9) - 
Clopidogrel 88(13.1) 38(16.4) 7(10.3) 0.267 
Aspirin+Clopidogrel  20(3.0) 12(5.2) 3(4.4) 0.238 
Aspirin+Dipyridamole 43(6.4) 13(5.6) 4(5.9) 0.948 
Ticlopidine 13(1.9) 7(3.0) 0(0.0) 0.291 
Aspirin+Ticlopidine  2(0.3) 0(0.0) 0(0.0) 1.000 
Carbasalate 6(0.9) 0(0.0) 0(0.0) 0.467 
Dipyridamole 4(0.6) 2(0.9) 0(0.0) 0.774 
Ozagrel 0(0.0) 0(0.0) 1(1.5) 0.076 
Triflusal 2(0.3) 0(0.0) 0(0.0) 1.000 
*Compared with aspirin.  
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Table 5. Frequency of bleeding events following antiplatelet exposure 
Bleeding 
No. (%) 
Persistent 
user 
n=670 
Early 
cessation user 
n=232 
Interrupted/ 
Stopped user 
n=68 
Overall 
n=970 
ICH 7(1.1) 6(2.7) 5(7.5) 18(1.9) 
ECH 21(3.2) 12(5.4) 2(2.9) 35(3.7) 
Total bleeding 28(4.2) 18(7.6) 7(10.3) 53(5.5) 
ICH, intracranial haemorrhage; ECH, extracranial haemorrhage.  
 This article is protected by copyright. All rights reserved. 
Table 6. Univariate analyses (conditional logistic regression) of selected variables against 
outcome of being “case” 
Characteristics 
No. (%) 
Unadjusted  
OR (95% CI) 
p-value Cases 
n=194 
Controls 
n=776 
Ethnicity      
Caucasian 161/187 (86.1) 647/747 (86.6) 0.94 (0.58-1.51) 0.782 
Others 26/187 (13.9) 100/747 (13.4) 1.00  
Smoking history       
Current Smoker 60/187 (32.1) 207/749 (27.6) 1.25 (0.87-1.79) 0.219 
Non/Former Smoker 127/187 (67.9) 542/749 (72.4) 1.00    
Baseline NIHSS* 11.5 (8-17) 12 (8-17) 0.99 (0.97-1.02) 0.886 
Medical history     
Hypertension       
Yes 147/194 (75.8) 545/753 (72.4) 1.19 (0.82-1.72) 0.356 
No 47/194 (24.2) 208/753 (27.6) 1.00    
Diabetes       
Yes 61/194 (31.4) 167/776 (21.5) 1.71 (1.20-2.46) 0.003 
No 133/194 (68.6) 609/776 (78.5) 1.00    
Atrial fibrillation       
Yes 37/194 (19.1) 122/753 (16.2) 1.27 (0.82-1.95) 0.285 
No 157/194 (80.9) 631/753 (83.8) 1.00    
Heart failure       
Yes 20/184 (10.9) 45/675 (6.7) 1.80 (1.01-3.20) 0.046 
No 164/184 (89.1) 630 (93.3) 1.00    
IHD       
Yes 57/187 (30.5) 186/728 (25.5) 1.26 (0.89-1.80) 0.208 
No 130/187 (69.5) 542/728 (74.5) 1.00    
Previous TIA       
Yes 19/176 (10.8) 50/725 (6.9) 1.78 (1.01-3.15) 0.049 
No 157/176 (89.2) 675/725 (93.1) 1.00    
Previous stroke       
Yes 40/186 (21.5) 137/700 (19.6) 1.08 (0.72-1.62) 0.700 
No 146/186 (78.5) 563/700 (80.4) 1.00    
rt-PA       
Yes 70 (36.1) 248 (32.0) 1.20 (0.87-1.66) 0.267 
No 124 (63.9) 528 (68.0) 1.00    
Antiplatelet exposures       
Early cessation 48 (24.7) 184 (23.7) 1.07 (0.67-1.71) 0.784 
Stopped/Interrupted 10 (5.2) 58 (7.5) 0.67 (0.34-1.36) 0.269 
Persistent  136 (70.1) 534 (68.8) 1.00  
All values are reported as no. (%) unless otherwise noted. †Values are reported as median 
(IQR). CI, confidence interval; IHD, ischaemic heart disease; IQR, interquartile range; 
NIHSS, National Institute Health Stroke Scale; OR, odds ratio; TIA, transient ischaemic 
attack; rt-PA, recombinant tissue plasminogen activator.  
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Table 7. Multivariable conditional logistic regression of explanatory variables against 
outcome of being “case” 
Characteristics Adjusted OR (95% CI) p-value* 
First model, all variables   
Caucasian 0.89 (0.52-1.54) 0.684 
Current Smoker 1.18 (0.77-1.81) 0.442 
Baseline NIHSS 0.98 (0.95-1.02) 0.331 
Hypertension 1.04 (0.65-1.67) 0.862 
Diabetes 1.60 (1.03-2.49) 0.036 
Atrial fibrillation 1.32 (0.76-2.29) 0.318 
Heart failure  1.33 (0.69-2.55) 0.398 
Ischemic heart disease 0.99 (0.65-1.50) 0.964 
Previous TIA 2.15 (1.15-4.01) 0.016 
Previous stroke 0.97 (0.59-1.59) 0.896 
rt-PA 1.05 (0.72-1.54) 0.787 
Early cessation†  1.09 (0.60-1.96) 0.779 
Stopped/Interrupted† 0.72 (0.32-1.65) 0.441 
Final model      
Diabetes 1.72 (1.170-2.52) 0.006 
Previous TIA 1.90 (1.06-3.40) 0.031 
Early cessation AP† 1.04 (0.62-1.74) 0.876 
Stopped/Interrupted AP† 0.70 (0.33-1.480) 0.352 
*Adjusted for other variables in model. †Compared to Persistent users. AP, antiplatelet; CI, 
confidence interval; NIHSS, National Institutes of Health Stroke Scale; OR, odds ratio; rt-PA, 
recombinant tissue plasminogen activator; TIA, transient ischaemic attack.  
 This article is protected by copyright. All rights reserved. 
Tables of Links 
 
    
 
 
 
 
 
 
 
 
These Tables of Links list key protein targets and ligands in this article that are hyperlinked* 
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from the IUPHAR/BPS Guide to PHARMACOLOGY [29], and are permanently archived in 
the Concise Guide to PHARMACOLOGY 2015/16 [30-34]. 
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